Guías clínicas de la enfermedad de Chagas 2006: Parte VI. Tratamiento antiparasitario de la enfermedad de Chagas

11Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

Abstract

As expert consensus has been arisen about universal antiparasitic treatment for all patients infected with Trypanosoma cruzi, most important drugs licensed for Chagas disease treatment are reviewed: nifurtimox and benznidazol, their mechanisms of action, doses, treatment schedules, adverse effects and contraindications. Two other drugs used for Chagas disease treatment, for which a Chilean experience may be exhibited, are allopurinol and itraconazole. Indications for treatment of Chagas disease in immunocompetent patients and inmunocompromised hosts are detailed. This chapter refers besides to the evaluation and monitoring of antiparasitic therapy in inmunocompromised patients, the availability of drugs and includes various forms facsímiles suggested to perform clinical and laboratory follow up of patients that undergo treatment, indicating the prescribed drug, adverse effects and time of follow up. © 2008 Sociedad Chilena de Infectología.

Cite

CITATION STYLE

APA

Apt B., W., Heitmann G., I., Jercic L., M. I., Jofré M., L., Muñoz C. Del V., P., Noemí H., I., … Zulantay A., I. (2008, October). Guías clínicas de la enfermedad de Chagas 2006: Parte VI. Tratamiento antiparasitario de la enfermedad de Chagas. Revista Chilena de Infectologia. https://doi.org/10.4067/s0716-10182008000500013

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free